187 participants randomized to trofinetide (n = 93) or placebo (n = 94); 155 participants (82.9%) completed the study (trofinetide, n = 70 (75.3%); placebo, n = 85 (90.4%)
From the trial
About 75% on trofinetide completed the trial
https://www.nature.com/articles/s41591-023-02398-1#:~:text=In%20this%20phase%203%20study%20in%20a%20large%20cohort%20of,and%20key%20secondary%20efficacy%20endpoints.
Ann: Q4 2023 quarterly activity report, page-18
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.64 |
Change
-0.110(0.70%) |
Mkt cap ! $2.019B | |||
| Open | High | Low | Value | Volume |
| $15.88 | $15.93 | $15.41 | $2.198M | 140.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 290 | $15.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.64 | 289 | 9 |
View Market Depth
| Last trade - 12.52pm 28/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |